# Oncology
Latest news and articles about Oncology
Total: 10 articles found
mRNA’s New Frontier: MIT Breakthrough Signals an End to ‘Untreatable’ Solid Tumors
Researchers from MIT and MGH have developed a groundbreaking mRNA-based adjuvant that cleared solid tumors in aggressive animal models. By reprogramming dendritic cells to enhance T-cell responses, the study published in Nature Biotechnology offers a potential breakthrough for treating 'cold' tumors that are currently resistant to standard immunotherapy.
China’s Biotech Coming of Age: Hengrui and BMS Strike Record $15.2 Billion Alliance
Hengrui Pharmaceuticals and Bristol Myers Squibb have signed a landmark $15.2 billion strategic partnership to develop 13 early-stage drug candidates. The deal marks a record for Chinese biotech out-licensing and underscores the growing global reliance on Chinese innovation to replenish pharmaceutical pipelines.
The New Vanguard: China’s Biotechs Shift from Mimicry to Mastery at ASCO 2026
China has achieved a record-breaking presence at the 2026 ASCO conference, securing nearly 20% of the world's Late-Breaking Abstracts. This surge reflects a decade-long transition from generic drug manufacturing to leading-edge oncology innovation in fields like ADCs and bispecific antibodies.
Chasing the Holy Grail: HEC Pharm’s Triple Threat at AACR 2026 Signals China’s Oncology Pivot
HEC Pharm presented three innovative oncology candidates at the 2026 AACR meeting, showcasing breakthroughs in Pan-RAS molecular glues, bispecific antibodies, and oral PD-L1 inhibitors. This move highlights the company's strategic pivot toward high-complexity R&D and its ambition to compete in the global precision medicine market.
Eli Lilly Bets $7 Billion on the ‘Holy Grail’ of Cancer Therapy to Diversify Beyond Weight Loss
Eli Lilly is acquiring Kelonia Therapeutics for up to $7 billion to gain access to its revolutionary in-vivo CAR-T technology. This strategic move aims to diversify Lilly's portfolio beyond its successful weight-loss business and establish a leading position in the high-growth oncology market.
Salubris Biotherapeutics Unveils Promising Clinical Data for Novel ADC, Signaling China’s Global Precision Oncology Push
Salubris Biotherapeutics has reported positive Phase 1/2 clinical data for its 5T4-targeting ADC, JK06, at the AACR 2026 conference. The drug shows promising safety and efficacy in treating advanced lung and breast cancers, marking a key advancement in the company's international clinical pipeline.
China’s Nuclear Medicine Leap: Beijing Approves World-First Domestic Radiopharmaceutical
China has approved its first self-developed, world-first radiopharmaceutical, marking a transition from drug imitation to global leadership. This breakthrough in nuclear medicine underscores Beijing's successful integration of biotechnology and nuclear infrastructure.
Precision Oncology Meets Generative AI: Yidu Tech’s Strategic Win at Beijing Cancer Hospital
Yidu Tech has won a 4.88 million RMB bid to implement large language model (LLM) infrastructure at the Peking University Cancer Hospital. This project, funded via a bank-medical partnership, aims to set a new industry benchmark for specialized AI applications in oncology.
China’s Oncology Frontier: Bioken’s Breakthrough Signals New Global Standard in Lung Cancer Treatment
Chinese biotech firm Bioken has reported record-breaking Phase II clinical results for its bispecific ADC lung cancer treatment, achieving a 100% tumor shrinkage rate in target lesions. Backed by a historic $8.4 billion deal with Bristol Myers Squibb, the company’s success highlights China’s rapid ascent from a generic drug producer to a leader in original pharmaceutical innovation.
Precision Oncology Gains Ground in China: AmoyDx Secures Regulatory Nod for c-Met Lung Cancer Diagnostic
Amoy Diagnostics has received NMPA approval for its c-Met gene amplification kit, a companion diagnostic for the lung cancer drug Savolitinib. This development marks a vital step in China's push for localized precision oncology and sophisticated personalized medicine tools.